Intellectual Property India Publishes Patent Application for 'A Nanostructured Apixaban Pharmaceutical Composition With Anti-Maillard Excipient System And Stabilizing Protective Matrix' Filed by Mr. Kunal Bhalerao Bachchhao; Prof. Ajaygiri Kamalgiri Goswami; Mr. Vijay Haribhau Bankar; Mr. Vijay Deepchand Gurudasani; Dr. Bhushan Ramachandra Dravyakar; Dr. Gajadhar K. Bhagat; Dr. Sunil Jayant Kulkarni; and Mr. Abhishek Sham Chichole

MUMBAI, India, May 29 -- Intellectual Property India has published a patent application (202621043862 A) filed by Mr. Kunal Bhalerao Bachchhao; Prof. Ajaygiri Kamalgiri Goswami; Mr. Vijay Haribhau Bankar; Mr. Vijay Deepchand Gurudasani; Dr. Bhushan Ramachandra Dravyakar; Dr. Gajadhar K. Bhagat; Dr. Sunil Jayant Kulkarni; and Mr. Abhishek Sham Chichole, Jalgaon, Maharashtra, on April 6, for 'a nanostructured apixaban pharmaceutical composition with anti-maillard excipient system and stabilizing protective matrix.'

Inventor(s) include Mr. Kunal Bhalerao Bachchhao; Prof. Ajaygiri Kamalgiri Goswami; Mr. Vijay Haribhau Bankar; Mr. Vijay Deepchand Gurudasani; Dr. Bhushan Ramachandra Dravyakar; Dr. Gajadhar K. Bhagat; Dr. Sunil Jayant Kulkarni; and Mr. Abhishek Sham Chichole.

The application for the patent was published on May 29, under issue no. 22/2026.

According to the abstract released by the Intellectual Property India: "The present invention relates to a stabilized pharmaceutical composition of Apixaban comprising a non-reactive, anti-Maillard excipient system and a protective stabilizing matrix. The composition includes Apixaban encapsulated within nanostructured carriers selected from polymeric nanoparticles, solid lipid nanoparticles (SLNs), or nanostructured lipid carriers (NLCs), having a particle size of 50-200 nm. The formulation further comprises non-reducing excipients such as trehalose, mannitol, or isomalt configured to inhibit amine-carbonyl interactions and prevent Maillard-type degradation. A polymeric stabilizing matrix comprising hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), or ethyl cellulose provides physical isolation of Apixaban. Stabilizing agents and pH-modifying components maintain a controlled microenvironment with pH below 6 and reduced moisture content. The composition prevents formation of Apixaban-excipient adducts, preserves molecular integrity, and maintains binding affinity towards Factor Xa, thereby ensuring sustained anticoagulant activity, improved prothrombin time, enhanced stability, and consistent therapeutic performance."

Disclaimer: Curated by HT Syndication.